glp-1 and sarcopenia GLP-1-derived therapies sarcopenia: plea for a specific focus on at risk special populations Obesity pharmacotherapy in older adults:

10.1038/s41598-021-88612-x 45 KimM.PlattM

Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T

Click here for all the Member Benefits.Show notesA bonus hype show ahead of Sunday's World Cup round of 16 between Mexico and England, where altitude has become the story everyone is talking about

It has also been shown to have important glucoregulatory effects, with chronic treatment in T2D individuals resulting in attenuated fasting plasma glucose levels and improved hemoglobin A1c levels [39]

Therefore, the US Food and Drug Administration (FDA) prohibits these therapies for patients with an individual or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN2)

However, the research on this is mixed